BeiGene (NASDAQ:ONC) Bolsa

BeiGene

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

BeiGene, Ltd. - American Depositary Shares

BeiGene Ltd

ON4 COMMUNS INC by On4 Communications, Inc.

On4 Communications Inc

Onconetix Inc

141 CAPITAL INC by 141 Capital, Inc.

Oncorus Inc rdinary Shares

ONCOSEC MEDICAL INC NEW by OncoSec Medical Incorporated

OncoSec Medical Inc

Oncternal Therapeutics Inc

Oncolytics Biotech Inc

Bragg Gaming Group ((<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;,%20url=https%3A%2F%2Fwww.nasdaq.com%2Fmarket-activity%2Fstocks%2Fbrag&amp;,%20esheet=54242956&amp;,%20newsitemid=20250423178093&amp;,%20lan=en-US&amp;,%20anchor=NASDAQ%3A+BRAG&amp;,%20index=1&amp;,%20NASDAQ:%3Ca%20class=">BRAG</a>, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;,%20url=https%3A%2F%2Fmoney.tmx.com%2Fen%2Fquote%2FBRAG&amp;,%20esheet=54242956&amp;,%20newsitemid=20250423178093&amp;,%20lan=en-US&amp;,%20anchor=TSX%3A+BRAG&amp;,%20index=2&amp;,%20TSX:%3Ca%20class=">BRAG</a>) ("Bragg" or the "Company"), a leading global B2B iGaming content and technology provider, today announced it has reached an agreement with its lenders, certain entities controlled by Doug Fallon, to repay USD 5 million of its outstanding USD 7 million secured promissory note and to extend the maturity of the remaining USD 2 million until June 6, 2025 (the "Note").
All other terms of the original Note remain unchanged. Bragg intends to repay the remaining USD 2 million balance on or before the amended June 6, 2025 maturity date.
 &nbsp;

News

BRAG

Bragg Gaming Group To Settle $5M Of Secured Promissory Note; To Extend Maturity Of Remaining $2M Until June 6, 2025

WIIM

Boyd Gaming shares are trading higher following better-than-expected Q1 financial results.

Hertz shares are trading lower following a report suggesting the company is looking to raise debt.

Eastman Chemical shares are trading lower after the company reported worse-than-expected Q1 sales results and issued Q2 adjusted EPS guidance below estimates.

<a href="https://www.youtube.com/watch?v=yMTbRJZQqyk" title="https://www.youtube.com/watch?v=yMTbRJZQqyk">https://www.youtube.com/watch?v=yMTbRJZQqyk</a>

Macro Economic Events

Econ #s

Economics

At SEC Roundtable When Asked About Delisting Chinese Companies, SEC Chairman Atkins Says Agency Will Take Action If Companies Do Not Abide by Laws

Flagstar Financial shares are trading higher following better-than-expected Q1 financial results.

VeriSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>) shares are trading higher on Friday after the company reported better-than-expected first-quarter earnings on Thursday after <a href="https://www.benzinga.com//node/44994822">the market closed.</a>
What To Know: The company reported earnings per share of $2.10, beating analysts&#8217; estimate of $2.09. In addition, the company reported sales of $402.30 million, beating analysts&#8217; estimate of $400.44 million.
VeriSign reported cash flow from operations of $291 million. It also ended the quarter with $649 million in cash, cash equivalents and marketable securities.
The company initiated a quarterly cash dividend of 77 cents per share.
Outlook: The company raised its sales guidance for fiscal-year 2025. It previously expected sales from $1.61 billion to $1.64 billion. It now expects sales from $1.64 billion to $1.65 billion, versus analysts&#8217; estimate of $1.62 billion.
See Also: <a href="https://www.benzinga.com/insights/news/25/04/45012242/1000-invested-in-cyberark-software-10-years-ago-would-be-worth-this-much-today">$1000 Invested In CyberArk Software 10 Years Ago Would Be Worth This Much Today</a>
VRSN Price Action: At the time of writing, VeriSign shares are trading 8.43% higher at $273.88, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: via Shutterstock

Movers

VRSN

What's Going On With VeriSign Shares Friday?

Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) shares dropped sharply after the company announced on Thursday <a href="https://www.benzinga.com/trading-ideas/movers/25/04/45011721/intel-just-announced-q2-guidance-below-estimates-why-the-stock-is-tumbling">disappointing second-quarter guidance</a>.
The announcement came amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst takeaways.
<h1 class="wp-block-heading">Rosenblatt Securities On Intel</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59972d99803ad30001fc246d/kevin-cassidy">Analyst Kevin Cassidy</a> maintained a Sell rating, while reducing the price target from $18 to $14.
Intel reported first-quarter revenue of $12.7 billion, down 11% sequentially and 1% year-on-year, although it beat consensus of $12.2 billion, Cassidy said in a note. Management expressed concern, however, that the beat was driven by "customers purchasing ahead of potential tariffs," which could impact demand in the second quarter, he added.
The company guided to second-quarter revenue of $11.8 billion at the mid-point, significantly missing consensus estimate of $12.8 billion, the analyst stated. "While coming into the year, growth seemed possible, Management is now seeing an increasingly uncertain economic landscape," he further wrote.
<h1 class="wp-block-heading">JPMorgan On Intel</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59f1c1bdefacff0001706787/harlan-sur">Analyst</a><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59f1c1bdefacff0001706787/harlan-sur"> Harlan Sur</a> reiterated an Underweight rating, while cutting the price target from $23 to $20.
While Intel reported its quarterly revenues, margins and earnings ahead of expectations, this was due to a "pull-forward in demand ahead of potential tariffs/trade-related dynamics," Sur said. Management guided to a 7% sequential decline in revenues in the second quarter, worse than consensus expectations of 5% growth, he added.
An uncertain macro environment due to tariff and trade dynamics puts Intel's TAM (total addressable market) growth outlooks at risk and could impact the company's performance in the seasonally stronger back half of the year, the analyst stated. 
"Intel should see a modest uplift in gross margins next year as it starts to move wafers in-house with 70% of Panther Lake logic silicon produced in-house," he further wrote. New CEO, Lip-Bu Tan, highlighted several new strategic initiatives including creating a flatter/leaner leadership structure in efforts to drive more costs out of the business and improve FCF generation.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
<h1 class="wp-block-heading">BofA Securities On Intel</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58a5e02943eaaa00018d9399/vivek-arya">Analyst </a><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58a5e02943eaaa00018d9399/vivek-arya">Vivek Arya</a> reaffirmed a Neutral rating and price target of $23.
Intel&#8217;s new CEO is "taking the right actions re focusing back on innovation, pruning costs, removing mgmt. layers etc," Arya said. He added, however, that the company's large size, unprofitable manufacturing, stiff competition from Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), Taiwan Semiconductor Manufacturing Co Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), NVIDIA Corp (NASDAQ:&nbsp;NVDA) and Arm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) make it more challenging to "turn things around in the next few years."
"The tariff environment adds further near-term headwinds," the analyst wrote. Intel could face continued gross margin headwinds through 2025 and 2026, he further stated.
<h1 class="wp-block-heading">Benchmark On Intel</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e2ae9e3430dee0001c80e0c/cody-acree">Analyst Cody Acree</a> reiterated a Hold rating on the stock.
Intel's quarterly earnings came in at 13 cents per share, coming in ahead of Street expectations by 12 cents per share, Acree said. The company guided to revenue of $11.2 billion to $12.4 billion, down 2% to 12% sequentially, below the consensus estimates, he added.
Intel expects customer activity to slow going ahead, driven by rising tariff and regulatory uncertainty as well as heightened risk of recession, the analyst stated. CEO Tan's long-term strategy is "likely to take at least several quarters before Intel's competitive position is even beginning to improve," he further wrote.
<h1 class="wp-block-heading">Cantor Fitzgerald On Intel</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e21cde3430dee0001c717dd/quinn-bolton">Analyst Quinn Bolton</a> maintained a Hold rating on the stock.
Intel reported strong results but guided to a decline in second-quarter revenues, Bolton said. "The outperformance in 1Q25 was largely attributed to order pull ins ahead of tariffs along with stronger than anticipated demand for the company&#8217;s Raptor Lake products," he added.
Management expects tariff risks to weigh on demand going ahead, the analyst stated. Due to this management gave a "wider than usual guidance range for 2Q25 ($11.2-$12.4BN)," he further wrote.
INTL Price Action: Shares of Intel had declined by 6.91% to $20.01 at the time of publication on Friday.
Read More: • <a href="https://www.benzinga.com/media/25/04/45008023/intel-weighs-taiwan-semiconductor-partnership-to-boost-chip-game">Intel Weighs Taiwan Semiconductor Partnership To Boost Chip Game</a>
Photo: Tada Images via Shutterstock

Analyst Color

Earnings Beats

Price Target

Reiteration

Analyst Ratings

Tech

Trading Ideas

INTC

INTL

Intel Shares Slide As Tariff Jitters Cloud Outlook, Analysts See More Challenges Despite New CEO Initiatives

DASH

Deliveroo Confirms That On April 5, 2025 It Received An Indicative Proposal From Doordash; Possible Offer From Doordash Of 180 Pence Per Deliveroo Share; Board Would Recommend Offer If Made On Current Terms; Doordash Must Announce Firm Intention May 23, 2025

Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders
Mouse analog of MICVO in a syngeneic model indicated strong activity of the cytotoxic Auristatin0101 payload and potential for MICVO monotherapy to drive immunogenic cell death, a key hypothesis for MICVO's mechanism
Combination of a mouse analog of MICVO and anti-PD-1 therapy in a syngeneic model resulted in enhanced tumor clearance and longer immunological memory compared to either treatment alone
Totality of pre-clinical data presented at AACR 2025 strongly support MICVO's unique, three-pronged mechanism of action of driving anti-tumor activity via direct tumor killing, bystander effect and immunogenic cell death, further reinforcing the potential patient benefit for MICVO as a monotherapy and in combination with an anti-PD-1 therapy
BOSTON, April 25, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, announced today robust preclinical data supporting the unique extracellular linker payload cleaving mechanism of action of micvotabart pelidotin (MICVO, formerly referred to as PYX-201) and validating MICVO's ongoing clinical development. MICVO is a first-in-concept antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix. This is a compelling target for cancer therapeutics as the physiological expression of EDB+FN is very low in healthy adult tissues while found to be highly expressed in a variety of solid tumor tissues. Data will be presented in two poster sessions on Monday, April 28 from 2:00 PM to 5:00 PM CT at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois.

PYXS

Pyxis Oncology Announces Robust Preclinical Data Supporting Unique Extracellular Linker Payload Cleaving Mechanism Of Action Of Micvotabart Pelidotin And Validating MICVO's Ongoing Clinical Development

<a href="https://www.youtube.com/watch?v=MZTUjr_lUiw">https://www.youtube.com/watch?v=MZTUjr_lUiw</a>

Politics

General

President Trump Says We'll Be Reasonable On Tariffs; Says Think Markets Are Adjusting To Tariff Policy

AT&amp;T Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) shares fell 2.8% to $26.73 during Friday&#8217;s session. The stock is likely moving lower in sympathy with rival T-Mobile Us Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>), which <a href="https://www.benzinga.com/news/earnings/25/04/44995935/t-mobile-shares-drop-despite-better-than-expected-q1-report-details">tumbled 11%</a> despite reporting record-breaking first-quarter results.
What To Know: Though T-Mobile delivered its best-ever first-quarter postpaid net additions and a 29% jump in diluted EPS, the market's negative reaction likely reflects investor unease over <a href="https://www.benzinga.com/pressreleases/25/04/b44994646/t-mobile-leads-the-industry-once-again-with-continued-durable-customer-growth-including-best-ever-">intense competitive pressures</a> and margin sustainability in the wireless space. 
T-Mobile's aggressive gains in postpaid phone subscribers and broadband customers signal heightened competition for AT&amp;T, particularly in high-margin service segments.
AT&amp;T, known for its diversified communications portfolio and emphasis on fiber and 5G expansion, may face increased pricing pressure and customer churn as T-Mobile's network and value proposition continue to strengthen. 
The selloff underscores investor worries that T-Mobile's growth, while impressive, could come at the expense of incumbents like AT&amp;T, pressuring future revenue and subscriber growth.
Read Also: <a href="https://www.benzinga.com/news/25/04/45010785/cantor-equity-partners-cep-stock-is-up-200-this-week-whats-happening">Cantor Equity Partners Stock Is Up 200% This Week: What&#8217;s Happening?</a>
<h2 class="wp-block-heading">How To Buy T Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in AT&amp;T&#8217;s case, it is in the Communication Services sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, T has a 52-week high of $29.03 and a 52-week low of $16.39.

TMUS

AT&T Shares Dip Following T-Mobile's Post-Earnings Selloff: What's Going On?

"White House Plans To Defund Bipartisan Social Security Advisory Board"

A Reddit user is getting honest about spending habits and asking for help.
User skylark178 <a href="https://www.reddit.com/r/budget/comments/1k0813i/i_spend_30_of_my_take_home_on_beauty_health_and/">posted</a> in the r/budget community that they spend roughly $1,750 every month on beauty, health and wellness expenses. With a take-home pay of $5,800, that&#8217;s 30% of their monthly income.
&#8220;Like many other Americans right now, I'm working on consuming less, <a href="https://www.benzinga.com/money/how-to-pay-off-debt">paying off debts</a>, and building a safety net for what seems to be the <a href="https://www.benzinga.com/markets/25/03/44211421/us-economy-teetering-recession-may-be-looming-as-bond-market-reacts-to-trump-policies">growing sh&#x2A;tshow</a> that is the U.S. economy, and I need a reality check,&#8221; the user wrote.
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>
<h2 class="wp-block-heading">Here's Where The Money Goes</h2>
The original post detailed monthly expenses:
<ul>
<li>$660 for weekly therapy (not covered by insurance)</li>
<li>$340 in sport/exercise fees (pickleball and table tennis)</li>
<li>$240 on massages (twice a month, 30% tip)</li>
<li>$155 on gel nails (two manis, one pedi, 30% tip)</li>
<li>$35 haircut</li>
<li>$35 for self-waxing</li>
<li>$85 on skincare (SPF, retinol, exfoliants, etc.)</li>
<li>$80 on hygiene products</li>
<li>$95 on prescriptions</li>
</ul>
The person also mentioned spending about $20 a month on workout shoes and clothes.
Reddit Responds: Treat Yourself Without Overspending
The post drew in dozens of responses, many of them supportive and filled with actionable advice.
The most common suggestion? Reduce the frequency of non-essential services and look for budget-friendly alternatives.
&#8220;Get one massage a month. Go to a free pickle bar court. Honestly, at this point, just buy a table tennis table for your house,&#8221; one user wrote.
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
Several users suggested cutting therapy to biweekly to save $330 a month.
On nails, people had a lot of ideas: switch to press-ons, go every three to four weeks, or do them at home. &#8220;The best nails I&#8217;ve seen are from people who do it themselves,&#8221; another user commented.
As for face products, one user said, &#8220;You do not need to be slathering $85 worth of stuff on your face every month.&#8221;
Others recommended bulk shopping at Costco, using dupes, or taking advantage of Black Friday sales.
<h2 class="wp-block-heading">OP Takes the Advice and Cuts $670 a Month</h2>
Skylark178 came back with an update: &#8220;Thanks everyone for the overall excellent feedback and suggestions! So appreciated. I now have a plan for reducing my b,h, and w spending from 30% to 19%.&#8221;
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
Here are the changes they plan to make:
<ul>
<li>Therapy reduced to twice a month: $330/month savings</li>
<li>One massage at a spa and one at a massage school: $90/month savings</li>
<li>Less frequent manis/pedis: $50/month savings</li>
<li>Sports expenses shared with family now: $170/month savings</li>
<li>Haircuts every 12 weeks instead of 8: $20/month savings</li>
<li>Cheaper skincare and bulk buying: $40/month savings</li>
</ul>
New total: $1,060 per month, or 19% of take-home pay. &#8220;This is my attempt to build legit savings,&#8221; OP said.
<h2 class="wp-block-heading">What the Community Appreciated Most</h2>
Even among the more critical responses, many users applauded the OP for <a href="https://www.benzinga.com/money/expense-tracker">tracking their spending</a> and being open to change.
&#8220;You're already doing something really powerful: tracking your spending and being honest with yourself. That's a huge first step,&#8221; one Redditor said.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>
Image: Shutterstock

Redditor Is Asking For Advice: 'I Spend $1750/Mo On Beauty, Health And Wellness, But I Only Take Home $5800/Mo. That's 30% Of Take-Home Pay'

Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology's investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and demonstrated promising anti-tumor activity
- Combination generated complete responses (CR) in 83% of patients with indolent relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) comparing favorably to 34% historical CR rate with R2 alone
- Phase 2 portion of trial in patients with previously untreated indolent NHL (iNHL) is ongoing and has completed enrollment
&nbsp;ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced encouraging data from an ongoing Phase 1/2 investigator-sponsored trial (IST) of the company's lead clinical candidate, evorpacept, in combination with standard-of-care rituximab and lenalidomide (R2) in patients with indolent and aggressive relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). Final results from the Phase 1 portion of the trial will be presented Tuesday, April 29, during a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois.&nbsp;
"In patients with indolent B-NHL, increases in certain pro-tumoral macrophages can promote resistance to important frontline standard-of-care treatments, including R2," said Paolo Strati, M.D., the trial's lead investigator and Associate Professor of Lymphoma-Myeloma at The University of Texas MD Anderson Cancer Center. "Evorpacept is uniquely designed to activate the innate immune system and engage macrophages to enhance the therapeutic benefits of and deepen responses to anti-cancer antibodies such as rituximab. This trial suggests evorpacept has a synergistic effect with R2 that may help improve outcomes and overcome resistance to R2 in this patient population."

Biotech

ALXO

ALX Oncology Announces Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma.  Combination Generated Complete Responses In 83% Of Patients With Indolent Relapsed Or Refractory B-cell Non-Hodgkin Lymphoma

Odyssey Marine Exploration Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>) shares are trading higher Thursday, extending the momentum from a major intraday spike driven by reports of a forthcoming U.S. executive order favoring t<a href="https://www.benzinga.com/news/25/04/44990450/why-odyssey-marine-exploration-omex-stock-is-exploding-higher">he deep-sea mining industry</a>.
What To Know: The rally builds on Thursday's earlier surge, when shares more than doubled following a Reuters report indicating that President Donald Trump is expected to sign an executive order designed to bypass international regulations in favor of a domestic permitting process.
The anticipated order would allow U.S.-based companies to seek deep-sea mining permits directly through the National Oceanic and Atmospheric Administration (NOAA) rather than the United Nations-backed International Seabed Authority. The move could significantly reduce regulatory friction for firms operating in this space, which investors appear to interpret as a catalyst for Odyssey Marine's stalled projects.
Odyssey, a Florida-based seafloor mineral exploration firm, is one of the few public companies in the U.S. with specialized capabilities and proprietary technology in deep-ocean mining. The prospect of a streamlined regulatory framework is being viewed as a potential unlock for billions in untapped undersea resources, including nickel, copper and rare earth elements critical for both the tech and defense industries.
Investors are betting that the policy shift could breathe new life into Odyssey's dormant projects in Mexican and South Pacific waters. The stock's continued upward movement suggests that speculation around this geopolitical development is driving renewed interest and positioning in the company.
OMEX Price Action: Odyssey Marine shares were up 76.0% at $1.49 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="531" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25115741/Screenshot-2025-04-25-at-11.57.23-1024x531.png" alt="" class="wp-image-889232" style="width:466px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25115741/Screenshot-2025-04-25-at-11.57.23-1024x531.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25115741/Screenshot-2025-04-25-at-11.57.23-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25115741/Screenshot-2025-04-25-at-11.57.23-768x398.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25115741/Screenshot-2025-04-25-at-11.57.23.png 1522w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45007990/stay-big-sell-rips-hartnett-doubts-bull-market-without-3-key-catalysts">&#8216;Stay BIG, Sell Rips&#8217;: Hartnett Doubts Bull Market Without 3 Key Catalysts</a></li>
</ul>
Image Created Via MidJourney.

OMEX

Odyssey Marine Exploration Stock Surges On Continued Momentum: What's Going On?

Susquehanna analyst Bascome Majors maintains TFI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFII#NYSE">TFII</a>) with a Positive and lowers the price target from $105 to $100.

TFII

Susquehanna Maintains Positive on TFI International, Lowers Price Target to $100

Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) shares are trading lower Friday despite the company announcing two significant developments aimed at boosting its autonomous driving capabilities and <a href="https://www.benzinga.com/25/04/44993180/pony-ai-shares-surge-after-hesai-lidar-partnership-announcement-whats-going-on">commercialization efforts.</a>
What To Know: Pony.ai announced a partnership with Tencent Cloud, the cloud arm of Chinese tech giant Tencent Holdings. The deal is positioned to integrate Pony.ai&#8217;s Robotaxi services with Tencent's digital platforms, including Weixin and Tencent Maps, to broaden user access and support large-scale deployment of autonomous mobility solutions in China. Tencent will also provide backend support in cloud computing, big data, and AI infrastructure to enhance Pony.ai's virtual simulation tool, PonyWorld, and improve its real-world readiness through advanced testing environments.
At the same time, Pony.ai is pushing forward with hardware upgrades through a separate partnership with Hesai Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>), selecting Hesai's AT128 lidar sensors as the primary system for its seventh-generation Robotaxi fleet. The announcement was made during the Shanghai International Automobile Industry Exhibition on Thursday, where Pony.ai showcased its new L4 autonomous driving platform. The platform includes four AT128 sensors per vehicle, supporting 360-degree obstacle detection and navigation in dense urban environments.
Pony.ai claims the new system reduces component costs by 70% compared to earlier models and is designed with a modular structure to streamline deployment across different vehicle types. The company also disclosed that its fleet has accumulated over 500,000 hours of fully driverless operation and reports a tenfold improvement in safety compared to human drivers.
PONY Price Action: Pony shares were down 5.94% at $7.12 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="536" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25115125/Screenshot-2025-04-25-at-11.51.05-1024x536.png" alt="" class="wp-image-889199" style="width:428px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25115125/Screenshot-2025-04-25-at-11.51.05-1024x536.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25115125/Screenshot-2025-04-25-at-11.51.05-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25115125/Screenshot-2025-04-25-at-11.51.05-768x402.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25115125/Screenshot-2025-04-25-at-11.51.05.png 1511w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45007990/stay-big-sell-rips-hartnett-doubts-bull-market-without-3-key-catalysts">&#8216;Stay BIG, Sell Rips&#8217;: Hartnett Doubts Bull Market Without 3 Key Catalysts</a></li>
</ul>

HSAI

PONY

Pony.ai Shares Volatile Amid Strategic Tencent Partnership And Hesai Lidar Integration: What's Going On?

U.S. Baker Hughes Oil Rig Count +2 To 483 U.S. Baker Hughes NatGas Rig Count Unchanged

Corporate Rebranding Marks New Era of Engineering Excellence and Sustainable Solutions
SINGAPORE, April 25, 2025 (GLOBE NEWSWIRE) -- SAG Holdings Limited today announced that it has changed its name to INNEOVA Holdings Limited ("INNEOVA Holdings" or the "Company"), (Nasdaq:&nbsp;SAG; new trading symbol INEO). INNEOVA Holdings is a Singapore-based provider of high-quality Original Equipment Manufacturer ("OEM"), third-party branded and in-house branded replacement parts for motor vehicles and non-vehicle combustion engines. The name change is part of the Company's comprehensive rebranding, and was approved by its shareholders on March 31, 2025. The Company trades on the the Nasdaq Capital Market and is changing its symbol from SAG to INEO, effective as of April 28, 2025
The Company is adopting the INNEOVA brand globally, reflecting its enhanced focus on engineering excellence and innovative solutions and is a key part of the Company's transformation strategy.

Comments

BeiGene

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL